JP2023518044A5 - - Google Patents
Info
- Publication number
- JP2023518044A5 JP2023518044A5 JP2022555714A JP2022555714A JP2023518044A5 JP 2023518044 A5 JP2023518044 A5 JP 2023518044A5 JP 2022555714 A JP2022555714 A JP 2022555714A JP 2022555714 A JP2022555714 A JP 2022555714A JP 2023518044 A5 JP2023518044 A5 JP 2023518044A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- solvate
- acceptable salt
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025033957A JP7892820B2 (ja) | 2020-03-16 | 2025-03-04 | Nlrp3モジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990363P | 2020-03-16 | 2020-03-16 | |
| US62/990,363 | 2020-03-16 | ||
| PCT/US2021/022397 WO2021188450A1 (en) | 2020-03-16 | 2021-03-15 | Nlrp3 modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025033957A Division JP7892820B2 (ja) | 2020-03-16 | 2025-03-04 | Nlrp3モジュレーター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518044A JP2023518044A (ja) | 2023-04-27 |
| JP2023518044A5 true JP2023518044A5 (cg-RX-API-DMAC7.html) | 2024-03-18 |
Family
ID=77747550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555714A Ceased JP2023518044A (ja) | 2020-03-16 | 2021-03-15 | Nlrp3モジュレーター |
| JP2025033957A Active JP7892820B2 (ja) | 2020-03-16 | 2025-03-04 | Nlrp3モジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025033957A Active JP7892820B2 (ja) | 2020-03-16 | 2025-03-04 | Nlrp3モジュレーター |
Country Status (16)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CA3175729A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| CN117247393A (zh) * | 2022-06-17 | 2023-12-19 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| WO2025255532A1 (en) * | 2024-06-07 | 2025-12-11 | Zomagen Biosciences Ltd | Combination therapies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2119705A1 (en) * | 2008-05-14 | 2009-11-18 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor |
| ES2668834T3 (es) * | 2008-09-08 | 2018-05-22 | Merck Serono Sa | Pirimidinas macrociclicas como inhibidores de proteína quinasas |
| CN107207431B (zh) * | 2015-01-13 | 2021-02-09 | 维夫雷昂生物科学有限责任公司 | Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途 |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| MA44729A (fr) * | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| UA126675C2 (uk) * | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| US11840543B2 (en) * | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| CN110914256A (zh) * | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| AU2018317800A1 (en) * | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| ES2927851T3 (es) | 2017-10-17 | 2022-11-11 | Novartis Ag | Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| US20200399242A1 (en) * | 2018-03-02 | 2020-12-24 | Inflazome Limited | Novel compounds |
| MA53172A (fr) * | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CA3175729A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
-
2021
- 2021-03-15 CA CA3175729A patent/CA3175729A1/en active Pending
- 2021-03-15 BR BR112022018480A patent/BR112022018480A2/pt not_active Application Discontinuation
- 2021-03-15 CN CN202180035570.2A patent/CN115605209B/zh active Active
- 2021-03-15 PH PH1/2022/552447A patent/PH12022552447A1/en unknown
- 2021-03-15 WO PCT/US2021/022397 patent/WO2021188450A1/en not_active Ceased
- 2021-03-15 MX MX2022011576A patent/MX2022011576A/es unknown
- 2021-03-15 JP JP2022555714A patent/JP2023518044A/ja not_active Ceased
- 2021-03-15 KR KR1020227035334A patent/KR20220154165A/ko active Pending
- 2021-03-15 AU AU2021237477A patent/AU2021237477A1/en active Pending
- 2021-03-15 EP EP21770604.3A patent/EP4121059A4/en active Pending
- 2021-03-15 IL IL296488A patent/IL296488A/en unknown
- 2021-03-15 AR ARP210100650A patent/AR121573A1/es unknown
- 2021-03-15 US US17/202,047 patent/US11603375B2/en active Active
- 2021-03-16 TW TW110109276A patent/TWI901652B/zh active
-
2022
- 2022-09-15 CL CL2022002531A patent/CL2022002531A1/es unknown
- 2022-10-12 CO CONC2022/0014499A patent/CO2022014499A2/es unknown
-
2023
- 2023-02-02 US US18/163,680 patent/US20230183258A1/en not_active Abandoned
- 2023-10-09 US US18/483,397 patent/US20240101571A1/en not_active Abandoned
-
2025
- 2025-03-04 JP JP2025033957A patent/JP7892820B2/ja active Active
- 2025-08-26 US US19/310,713 patent/US20260200935A1/en active Pending